Jade Biosciences, Inc. (JBIO)

NCM – Цена в реальном времени. Валюта: USD

23.15

+0.80 (3.58%)

Рынок открыт: Aug 12, 2026, 1:13 PM EDT

22.35

0.00 (0.00%)

Предыдущая сессия: Aug 11, 2026, 7:34 PM EDT

10.08.2026

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027 Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027 Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027 JADE301, a potentially best-in-class, half-life–extended anti-IFN-β for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of 2027 Cash, cash equivalents, and investments of $461 million as of June 30, 2026 expected to provide runway into the fourth quarter of 2028 SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the second quarter ending June 30, 2026, and provided a corporate update. “This was an important period for Jade as we reported positive interim Phase 1 data for JADE101 that exceeded our expectations across biomarker activity and durability, with a favorable safety profile, strengthening our conviction to rapidly advance the compound to deliver a potentially best-in-class profile in IgA nephropathy,” said Tom Frohlich, Chief Executive Officer of Jade Biosciences.

Видео

No Data

There is no data to display

Пресс-релизы

10.08.2026

Jade Biosciences, Inc. (JBIO)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Jade Biosciences, Inc. (JBIO)

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Search stocks

Jade Biosciences, Inc. (JBIO)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Jade Biosciences, Inc. (JBIO)

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update